Fundraising FoxHealthtech Startups
18,748 companies tagged Healthtech, with their investors and founders.
0 investors
0 investors
Absco Therapeutics develops a drug delivery platform based on thermogelling polymers that shift from liquid to solid at body temperature to form controlled-release depots for sustained, on-target therapy. Its lead candidate ABS005 is a non-surgical intralesional treatment for high-grade cervical intraepithelial neoplasia (CIN2/3), with the platform targeting cancers and precancers.
0 investors
0 investors
0 investors
ACatechol develops bioinspired surface treatment technologies to prevent infections in medical devices, particularly catheters, by inhibiting biofilm formation. The company serves hospitals and medical device manufacturers seeking to reduce catheter-related bloodstream infections and sepsis.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Accu-Break Pharmaceuticals develops patent-pending tablet technologies that let pharmaceutical tablets be swallowed whole or broken into precise half, third, or quarter doses using a pharmacologically inactive break region. Its technologies target drugmakers seeking dose flexibility, product life-cycle management, and extended patent protection.
0 investors
Accufy develops next-generation sequencing technology for multiomic analysis to enable early disease detection. The company serves biomedical research and diagnostics markets with proprietary NGS tagging and target enrichment platforms.
0 investors
0 investors
Accure develops an FDA-cleared, CE Mark–approved laser system that treats inflammatory acne by selectively targeting overactive sebaceous glands while sparing surrounding skin. The device is designed for dermatologists and acne patients, using a "treat-to-temperature" algorithm intended to work across all skin types.
0 investors
AccuVein manufactures vein visualization systems for medical professionals to locate veins during procedures. The company serves healthcare providers in clinical and procedural settings.
0 investors
0 investors
0 investors
Aces Diagnostics is developing LYMESEEK, an AI-driven blood test for detecting Lyme disease across all stages of the disease, aimed at physicians and clinical laboratories. The single blood-draw test runs on existing lab equipment and is being validated on clinical samples in the U.S. and E.U., with commercial launch anticipated in 2027.
0 investors
0 investors
0 investors
Achelios Therapeutics develops therapies for chronic pain conditions including temporomandibular joint pain, migraine, and arthritis-related joint pain through repurposed and reformulated drug candidates. The company addresses unmet medical needs in chronic pain that have been underserved by larger pharmaceutical firms.
0 investors